Dimerix (ASX:DXB) has announced it has received an R&D Tax Incentive rebate of $3.695 million for the 2020-21 year.
The company has near-term Phase 3 clinical studies in inflammatory diseases.
It is currently developing its proprietary product DMX-200 for Focal Segmental Glomerulosclerosis (FSGS), respiratory complications associated with COVID-19 and Diabetic Kidney Disease. It is developing DMX-700 for Chronic Obstructive Pulmonary Disease (COPD).
"During the 2021 financial year, we continued to deliver on our strategic goals as we expanded our programs to include supporting two global Phase 3 clinical studies, in an effort to develop a product that may help in the treatment of COVID-19 patients, as well as progress our renal program into a phase 3 clinical study and advance our longer-term opportunities," said CEO and managing director Dr Nina Webster.
"The Australian government's support of domestic research and development is invaluable and plays a critical role in supporting companies like Dimerix. We look forward to updating the market on these activities in due course."
